Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Altimmune (ALT) over the last 15 years, with Q3 2025 value amounting to $14.4 million.

  • Altimmune's Non-Current Debt changed N/A to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year change of. This contributed to the annual value of $4.6 million for FY2022, which is 21506.19% up from last year.
  • Latest data reveals that Altimmune reported Non-Current Debt of $14.4 million as of Q3 2025.
  • Altimmune's 5-year Non-Current Debt high stood at $14.4 million for Q3 2025, and its period low was $1.5 million during Q4 2021.
  • In the last 4 years, Altimmune's Non-Current Debt had a median value of $4.2 million in 2023 and averaged $4.6 million.
  • In the last 5 years, Altimmune's Non-Current Debt tumbled by 2047.88% in 2021 and then skyrocketed by 21506.19% in 2022.
  • Quarter analysis of 4 years shows Altimmune's Non-Current Debt stood at $1.5 million in 2021, then skyrocketed by 215.06% to $4.6 million in 2022, then decreased by 6.02% to $4.3 million in 2023, then skyrocketed by 235.54% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, $14.3 million for Q2 2025, and $4.3 million during Q3 2023.